StageZero Life Sciences has entered a collaboration to offer its multi-cancer blood test, Aristotle, to DiagnoseAtHome’s (DAH) patients in the US and Canada. 

Aristotle is a next-generation test based on StageZero’s messenger ribonucleic acid (mRNA) gene expression technology platform.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It is claimed to be the first-ever mRNA multi-cancer panel that can test for various cancers from a single blood sample concurrently with increased sensitivity and specificity for each cancer. 

StageZero noted that the Aristotle test identifies gene expression profiles that indicate specific cancers by interrogating mRNA from a whole blood sample. 

Furthermore, it can screen for molecular signatures linked to various individual cancers, including breast, ovarian, endometrial, colorectal, liver, stomach and prostate cancers.

StageZero Life Sciences chairman and CEO James Howard-Tripp said: “Our partnership with DiagnoseAtHome allows greater access to early cancer screening for their many clients and broadens the availability of Aristotle in Canada and the USA. 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Growing our patient base and expanding the availability of our early cancer test is a key pillar in our Growth Strategy.”

DAH provides accessible at-home health and lab testing solutions, permitting organisations, businesses and healthcare providers to deliver safe and precise lab testing to patients without the need for in-person visits to the laboratory. 

DiagnoseAtHome founder Dr Ian Plener said: “By onboarding Aristotle to the DAH platform, we are better able to provide our patients and providers with a novel approach to early cancer screening. 

“Growing our laboratory network will further enhance the breadth of curated laboratory solutions available to our growing patient and provider base.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact